What Is Selank? Where It Came From, and When

What is Selank? It is two things at once, and leaving out either half produces a misleading answer. It is a synthetic peptide derived from tuftsin, developed in Russia, studied as an anxiolytic, and registered as a medicine there, with a real clinical literature behind that registration. It is also a compound with no Western trial, no FDA, EMA or MHRA authorisation, and no presence in the evidence system a Western reader is unconsciously checking against.

Most English language pages carry one of those halves and quietly drop the other. This one runs through the origin in order, then the status now.

What is Selank, and what it is not

Start with the plain description before the complications.

It is a short synthetic peptide, built as a derivative of tuftsin, which is a peptide the body produces. That design choice is standard pharmaceutical reasoning: an endogenous peptide with known activity is a template, and modification aims at something stable and usable enough to function as a medicine.

It was developed in Russia, and it was aimed at anxiety from early on rather than at a general purpose. That focus is unusual among compounds sold in this market and it is worth noticing. Where a claim set fans out in every direction, the claims usually arrived after the science, from marketing. Here the target was named by the developers at the start, and the literature stayed close to it.

What it is not is an approved medicine outside Russia, a supplement, a nootropic with established cognitive effects, or a compound whose broader claims have been measured. It is also not, as several English language pages imply, an unstudied research chemical with nothing behind it. That description is as wrong as the opposite one.

The origin, step by step

Sequence makes the current position legible in a way a list of facts does not.

First came tuftsin itself and the interest in what a derivative of it might do. That is the chemistry step, and it sets the family the molecule belongs to.

Then came laboratory and animal work. In rats and mice, anxiety related behaviour is measured with standard behavioural tests: how an animal moves through open space, whether it enters exposed areas, how it responds to unfamiliar surroundings. Animals receiving the compound are compared against a control group. Those are real measurements of rodent behaviour, and a rodent reports nothing about how it feels, so what is recorded is what the animal does.

Then came clinical work in humans within that system, assessed the way psychiatric outcomes have to be assessed, using rating scales applied by clinicians rather than a laboratory test, because there is no blood test for anxiety.

Then came registration in Russia, the point at which it stopped being purely a research subject there and became an authorised product with labelling attached.

And then the sequence stopped at the border. No equivalent programme was run elsewhere. That is why this page cites no trial identifiers: there is no genuine registered Western trial of this compound, and identifiers that appear in keyword searches belong to studies of unrelated subjects.

Questions worth answering before the rest of this page

Why the word clinical is doing so much work

One word carries most of the confusion on this subject, and it is worth slowing down on.

When an English speaking reader sees that a compound has clinical evidence, a set of assumptions loads automatically. They assume a trial was registered publicly before it started, so it cannot be hidden if the result disappoints. They assume the endpoint was fixed in advance, so nobody chose it afterwards from whatever happened to move. They assume a placebo group, blinding, and publication in a journal where people with no stake in the outcome can attack the methods.

Those assumptions are about a process, not about a word. The word only means that people were studied. Everything else on that list is machinery built around the word in one particular system over several decades, largely in response to specific scandals.

Russian clinical research on this compound was conducted in a different system with different conventions on registration, publication, language and access. That is a statement about what a reader here can verify. It is not a claim that the work was fabricated or that the conclusions are wrong, and pages that slide from one to the other are overreaching in the opposite direction from the marketing.

The practical position for a reader is uncomfortable and worth sitting with rather than resolving. The evidence exists and cannot be checked by them. Neither confident dismissal nor confident endorsement is available, and anyone offering either is telling you about themselves rather than about the compound.

What it is, commercially, outside that jurisdiction

The regulatory picture determines what a buyer here is actually handling, and the gap is larger than most readers expect.

Inside Russia it is a manufactured pharmaceutical. Identity, quantity, purity and sterility are verified by parties with legal obligations, batches are traceable, and the product comes with labelling that a regulator reviewed, including the restrictions and warnings that occupy most of any real label's length.

Outside Russia it is sold as a research chemical, and that designation is best understood by what nobody is obliged to do. Nobody must confirm that the vial contains the compound named. Nobody must confirm the amount, the purity, or the absence of anything else. Nobody must confirm sterility. Nobody collects reports of harm, because there is no system collecting them for a substance no regulator has authorised.

The consequence is worth stating directly. The clinical literature, whatever weight a reader gives it, describes the first object. Almost every English speaking reader who buys this compound is holding the second one. Those are not the same thing, and an argument that moves from one to the other has skipped the step that matters most.

Where it would have to go from here

The missing document is specific, and naming it is more useful than describing the evidence as limited.

The two empty rows near the bottom are the whole gap. A registered Western trial would mean a study listed publicly before enrolment, with a protocol filed in advance, a placebo group, blinded assessors, an anxiety rating scale chosen ahead of time, and results published where people with no stake in them can criticise them.

Nothing in the existing record substitutes for that, and its absence is not evidence against the compound either. The accurate summary is that this molecule has a longer and more serious human history than most things sold beside it, in a system a Western reader cannot inspect, attached to a product a Western reader cannot buy.